KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Long-Term Debt Repayments (2019 - 2023)

Aquestive Therapeutics has reported Long-Term Debt Repayments over the past 3 years, most recently at $9.1 million for Q1 2023.

  • Quarterly results put Long-Term Debt Repayments at $9.1 million for Q1 2023, changed N/A from a year ago — trailing twelve months through Mar 2023 was $31.6 million (up 40.38% YoY), and the annual figure for FY2025 was $26000.0, up 13.04%.
  • Long-Term Debt Repayments for Q1 2023 was $9.1 million at Aquestive Therapeutics, down from $22.5 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for AQST hit a ceiling of $49.4 million in Q3 2019 and a floor of $9.1 million in Q1 2023.
  • Median Long-Term Debt Repayments over the past 3 years was $22.5 million (2020), compared with a mean of $27.0 million.